N

NeuroActiva, Inc.

15 employees

Dedicated to the discovery, development, and commercialization of new drugs to treat and prevent Alzheimer’s disease and Covid-19

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Multiple sclerosis
Parkinson's disease
Membrane controlled release optimization system
New drug discovery
ALS
FDA affairs
amyotrophic lateral sclerosis
Alzheimer drug developer
Micros Infuser
Vineurocin
regulatory affairs
neurogenesis
clinical trials
Alzheimer's disease
NA-704
NA-901
MICROS
Biopharmaceutical
Biopharmaceutical drug developer
pharmaceutical company
Traneurocin
neuroprotection
NA-831

FAQ